KR20070106029A - 상피세포 성장 인자 수용체 돌연변이 - Google Patents

상피세포 성장 인자 수용체 돌연변이 Download PDF

Info

Publication number
KR20070106029A
KR20070106029A KR1020077021517A KR20077021517A KR20070106029A KR 20070106029 A KR20070106029 A KR 20070106029A KR 1020077021517 A KR1020077021517 A KR 1020077021517A KR 20077021517 A KR20077021517 A KR 20077021517A KR 20070106029 A KR20070106029 A KR 20070106029A
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
leu
egfr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077021517A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 프리맨
토드 주안
로버트 래딘스키
Original Assignee
암젠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인코포레이티드 filed Critical 암젠 인코포레이티드
Publication of KR20070106029A publication Critical patent/KR20070106029A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
KR1020077021517A 2005-02-24 2006-02-23 상피세포 성장 인자 수용체 돌연변이 Withdrawn KR20070106029A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65626305P 2005-02-24 2005-02-24
US?60/656,263? 2005-02-24

Publications (1)

Publication Number Publication Date
KR20070106029A true KR20070106029A (ko) 2007-10-31

Family

ID=36579263

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077021517A Withdrawn KR20070106029A (ko) 2005-02-24 2006-02-23 상피세포 성장 인자 수용체 돌연변이

Country Status (15)

Country Link
US (2) US7981605B2 (enExample)
EP (1) EP1851243A2 (enExample)
JP (2) JP2008535477A (enExample)
KR (1) KR20070106029A (enExample)
CN (1) CN101208354A (enExample)
AU (2) AU2006216477A1 (enExample)
BR (1) BRPI0607235A2 (enExample)
CA (1) CA2601936C (enExample)
CR (1) CR9390A (enExample)
EA (1) EA013617B1 (enExample)
IL (1) IL185210A0 (enExample)
MX (1) MX2007009963A (enExample)
NO (1) NO20074826L (enExample)
WO (1) WO2006091899A2 (enExample)
ZA (1) ZA200707379B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200087726A (ko) * 2019-01-11 2020-07-21 주식회사 진캐스트 Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
KR20200087723A (ko) * 2019-01-11 2020-07-21 주식회사 진캐스트 Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
KR20200087727A (ko) * 2019-01-11 2020-07-21 주식회사 진캐스트 유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
WO2006086777A2 (en) 2005-02-11 2006-08-17 Memorial Sloan Kettering Cancer Center Methods and compositions for detecting a drug resistant egfr mutant
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
PL2132229T3 (pl) 2007-03-01 2016-12-30 Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka
EP2118322A2 (en) * 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
US8784623B2 (en) * 2008-07-17 2014-07-22 Koninklijke Philips N.V. Nanopore device and a method for nucleic acid analysis
EP2331577B1 (en) 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
US8623604B2 (en) * 2009-09-09 2014-01-07 Quintiles Transnational Corp. Methods for predicting responsiveness of a cancer cell to an anti-IGFR1 antibody by analysis of mutations in PIK3CA
JP5891172B2 (ja) * 2010-07-07 2016-03-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 正常乳腺上皮細胞からの腫瘍細胞の製造方法
US20120164641A1 (en) * 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
AU2012253525B2 (en) * 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
EP2554551A1 (en) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
KR20150136588A (ko) * 2013-01-14 2015-12-07 내셔널 타이완 유니버시티 Ｅｇｆｒ의 발현을 침묵시키기 위한 ｄｎａ자임
CN103739713B (zh) * 2013-12-10 2016-03-09 吴炯 一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB2521355A (en) * 2013-12-17 2015-06-24 Kymab Ltd Human targets I
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CN105779480B (zh) * 2016-03-24 2020-03-20 成都康景生物科技有限公司 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN108047308A (zh) * 2018-02-02 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108047309A (zh) * 2018-02-07 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250268A (zh) * 2018-02-08 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218959A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108409832A (zh) * 2018-03-07 2018-08-17 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218960A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218961A (zh) * 2018-03-19 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440649A (zh) * 2018-05-31 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108752424A (zh) * 2018-06-04 2018-11-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440650A (zh) * 2018-06-04 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440651A (zh) * 2018-06-08 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
TW202019421A (zh) * 2018-07-31 2020-06-01 大陸商蘇州亞盛藥業有限公司 Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого
US11459391B2 (en) 2019-02-26 2022-10-04 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CN113993544A (zh) * 2019-07-24 2022-01-28 神州细胞工程有限公司 用于治疗egfr高表达的癌症的多变剂量方法
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
ATE135373T1 (de) * 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
CA2408175A1 (en) * 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample
WO2005027710A2 (en) * 2002-09-11 2005-03-31 Sequenom, Inc. Methods for identifying subjects at risk of melanoma and treatments thereof
EP2439285B1 (en) * 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2592155B2 (en) * 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
AU2005287404B2 (en) * 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
PT2332909E (pt) * 2005-04-13 2014-12-17 Astex Therapeutics Ltd Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90
WO2007001868A1 (en) 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200087726A (ko) * 2019-01-11 2020-07-21 주식회사 진캐스트 Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
KR20200087723A (ko) * 2019-01-11 2020-07-21 주식회사 진캐스트 Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
KR20200087727A (ko) * 2019-01-11 2020-07-21 주식회사 진캐스트 유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법

Also Published As

Publication number Publication date
AU2006216477A1 (en) 2006-08-31
CA2601936C (en) 2014-06-17
EP1851243A2 (en) 2007-11-07
BRPI0607235A2 (pt) 2009-08-25
NO20074826L (no) 2007-11-23
EA013617B1 (ru) 2010-06-30
ZA200707379B (en) 2008-10-29
US8546107B2 (en) 2013-10-01
IL185210A0 (en) 2008-01-06
CA2601936A1 (en) 2006-08-31
US20120328620A1 (en) 2012-12-27
US20070048754A1 (en) 2007-03-01
AU2010241462A1 (en) 2010-12-16
WO2006091899A3 (en) 2007-02-22
MX2007009963A (es) 2007-09-26
JP2012149070A (ja) 2012-08-09
US7981605B2 (en) 2011-07-19
JP2008535477A (ja) 2008-09-04
WO2006091899A2 (en) 2006-08-31
CR9390A (es) 2008-01-02
EA200701804A1 (ru) 2008-06-30
CN101208354A (zh) 2008-06-25

Similar Documents

Publication Publication Date Title
US8546107B2 (en) Epidermal growth factor receptor mutations
US11155876B2 (en) K-ras mutations and anti-EGFr antibody therapy
EP2412828B1 (en) K-ras and B-raf mutations and anti-EGFr antibody therapy
AU2013201896A1 (en) Epidermal growth factor receptor mutations
AU2018219977B2 (en) K-ras mutations and anti-EGFr antibody therapy field
HK1172372A (en) K-ras mutations and anti-egfr antibody therapy
HK1172372B (en) K-ras mutations and anti-egfr antibody therapy
AU2014206164A1 (en) K-ras mutations and anti-EGFr antibody therapy field
HK1167005B (en) K-ras and b-raf mutations and anti-egfr antibody therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070919

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid